首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BAFF |
| Uniprot No | Q9Y275 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 134-285aa |
| 氨基酸序列 | AVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL |
| 预测分子量 | 46.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BAFF重组蛋白的3篇经典文献及其摘要概括：
---
1. **"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell proliferation"**
*Schneider, P., et al. (1999), Journal of Experimental Medicine*
首次克隆并表达重组BAFF蛋白，证实其通过结合受体TACI和BCMA促进B细胞增殖与存活，揭示了BAFF在B细胞稳态中的关键作用。
2. **"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations"**
*Mackay, F., et al. (1999), Journal of Experimental Medicine*
利用重组BAFF构建转基因小鼠模型，发现BAFF过表达导致B细胞过度活化及系统性红斑狼疮样自身免疫表型，提示BAFF在自身免疫疾病中的病理机制。
3. **"BAFF selectively enhances survival of transitional immature B cells"**
*Do, R.K., & Chen-Kiang, S. (2002), Journal of Immunology*
通过体外重组BAFF处理不同发育阶段的B细胞，证明BAFF特异性促进未成熟过渡态B细胞的存活，解析了其在B细胞成熟中的调控机制。
---
以上文献均聚焦于重组BAFF蛋白的功能研究，涵盖分子机制、疾病模型及细胞信号通路等领域。如需更多应用类研究(如药物开发)，可进一步补充。
BAFF (B cell-activating factor), also known as TNF superfamily member 13B (TNFSF13B), is a critical cytokine involved in B cell survival, proliferation, and differentiation. It binds to three receptors: BAFF-R, TACI, and BCMA, which are expressed on B cells and plasma cells. Discovered in 1999. BAFF plays a central role in maintaining B cell homeostasis and adaptive immunity. Dysregulation of BAFF signaling is linked to autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis) and B cell malignancies, making it a key therapeutic target.
Recombinant BAFF protein is produced using genetic engineering techniques, typically in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and functional activity. This engineered protein retains the native trimeric structure required for receptor binding and biological function. Its production enables controlled in vitro and in vivo studies of B cell biology, immune regulation, and disease mechanisms.
In research, recombinant BAFF is widely used to investigate B cell development, antibody production, and pathological processes in autoimmune disorders. It also serves as a tool for screening BAFF inhibitors, such as belimumab—the first FDA-approved anti-BAFF monoclonal antibody for lupus treatment. Additionally, it has potential applications in vaccine development by enhancing B cell responses. As a standardized reagent, recombinant BAFF ensures reproducibility in studies exploring immune modulation, drug discovery, and therapeutic interventions targeting the BAFF/APRIL signaling axis. Its availability accelerates both basic research and translational efforts in immunology and immunotherapy.
×
